Biotech

Sanofi Boosts Alzheimer's Pipeline With Vigil Neuroscience Acquisition

What's Going On With UroGen Pharma Stock Wednesday?

EXCLUSIVE: Telomir Pharma To Raise $3 Million Via Equity Financing To Fund Its Rare Disease IND

What's Going On With UroGen Pharma Stock Wednesday?

EXCLUSIVE: Telomir Pharma To Raise $3 Million Via Equity Financing To Fund Its Rare Disease IND

Elon Musk Says Neuralink Has Implanted Brain Chips In 5 Humans—Next Up: Restoring Vision With 'Blindsight' By 2026

FDA Limits Annual COVID-19 Boosters To High-Risk Americans, Demands New Trials For Healthy Adults In Policy Shift Under RFK Jr.

Elon Musk Says Neuralink Has Implanted Brain Chips In 5 Humans—Next Up: Restoring Vision With 'Blindsight' By 2026

FDA Limits Annual COVID-19 Boosters To High-Risk Americans, Demands New Trials For Healthy Adults In Policy Shift Under RFK Jr.

Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal

The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants

Biotech Recent News

EXCLUSIVE: GT Biopharma Advances Relapsed Blood Cancer Therapy Trial To Cohort 2 After Promising Early Safety Results

GTBP announces completion of dosing in Cohort 1 and start of dosing in Cohort 2 of Phase 1 trial for GTB-3650, showing potential for NK cell expansion and increased immunologic activity. Detailed results to be released in 2025. GTBP stock up 0.90%.

Rocket Pharma's Gene Therapy Shows Promise in ACM Patients, Says Analyst

Chardan's Geulah Livshits raises target price for RCKT to $46 and maintains Buy rating after promising data on gene therapy for heart disease.

Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%

Carl Icahn boosts holdings in Illumina and JetBlue, showing confidence in biotech and airlines. He also trims exposure to Southwest Gas Holdings.

A DeepSeek Moment For Anti-Ageing? Eastenova's XH301 Outshines Hyaluronic Acid Product In Clinical Trial

A treatment to smooth out smile lines was more effective than imported hyaluronic acid products in a clinical trial.

Eli Lilly Collaborates With Rznomics On Hearing Loss Treatment In $1.3 Billion Pact

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential deal value above $1.3 billion.

Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda

Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors.

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

Immutep's efti combo with Keytruda and chemo shows a 60.8% response rate in lung cancer trial, with strong efficacy across PD-L1 expression levels.

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

Nkarta posts a smaller Q1 loss than expected and maintains strong cash reserves while analysts debate its trial strategy and market position.

Why Is Biohaven Stock Falling On Thursday?

Biohaven secures $250 million from Oberland Capital, with total cash reaching $518 million to support troriluzole launch and operations.

Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025

For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.

From Cancer Drugs To Cosmetics: A Cash-strapped Company's Makeover Story

This cash-strapped company is shifting from its roots in cancer drug development to focus on cosmetic treatments.

Incannex Healthcare (IXHL) Stock Soars Over 800%: What's Going On?

The drug could could offer a pharmacological alternative to CPAP devices.

Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030

Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.